| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) | |
| US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) | |
| US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) | |
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(1 year, 9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(4 years ago) | |
|
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(1 year, 3 months ago) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(3 years from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(3 years from now) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(3 years from now) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(3 years from now) | |
Toviaz is owned by Pfizer.
Toviaz contains Fesoterodine Fumarate.
Toviaz has a total of 12 drug patents out of which 6 drug patents have expired.
Expired drug patents of Toviaz are:
- US7855230
- US6858650*PED
- US7384980
- US7985772
- US8338478
- US6858650
Toviaz was authorised for market use on 31 October, 2008.
Toviaz is available in tablet, extended release;oral dosage forms.
Toviaz can be used as treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Drug patent challenges can be filed against Toviaz from 18 December, 2023.
The generics of Toviaz are possible to be released after 07 December, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
TOVIAZ family patents
